By A subcutaneously implanted, catheter-pump system capable of chronic convection-enhanced delivery (CED) of topotecan is well tolerated and active for patients with recurrent glioblastoma, according to a study published in the November issue of The Lancet Oncology.
Convection-enhanced delivery of topotecan active in glioblastoma
Cloud computing banner background for smart city
Comments